NCT00124943View on ClinicalTrials.gov

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Coronary Restenosis
Interventions
DRUG

Nanoparticle Paclitaxel

Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY